Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The study is a randomized melanoma trial using Signatera to guide early immunotherapy escalation in advanced or metastatic patients with persistent molecular residual disease despite initial treatment; results have not been presented.
Natera said it enrolled the first patients in a randomized Signatera-guided interventional trial in melanoma sponsored by NYU Langone Health (NCT07504796).